RBC lifted its price objective for Bio-Rad Laboratories, and Citigroup also raised its price objective for the company.
3 reports, 1 independent
Updated Aug 17
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
RBC lifted its price objective for Bio-Rad Laboratories, and Citigroup also raised its price objective for the company.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Bio-Rad Laboratories
American life science research firm
- Strategic acquisitions and product launches are driving growth for Bio-Rad Laboratories in the life science ddPCR and clinical diagnostics markets.
- Bio-Rad Laboratories is applying digital PCR technology through current partnerships, including Biodesix, Gencove, Insight Molecular, and Stilla Technologies.
-
Royal Bank of Canada
financial institution in Canada
-
Citigroup
American investment bank and financial services corporation
Related events
- RBC raised its target price for Howmet Aerospace, while Citigroup reiterated a 'buy' rating on the shares.
- Bio-Rad Laboratories filed its required 13F reports with the SEC on September 7, 2026.
- Analyst firms RBC, CLSA, Morgan Stanley, and Jefferies Financial Group provided rating and price target updates for Thermo Fisher Scientific on September 8, 2026.